Please ensure Javascript is enabled for purposes of website accessibility

Abbott's Brain Stimulation System Approved to Treat Parkinson's

By Mark Prvulovic - Updated Jan 24, 2020 at 3:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This system now has approval to target all areas of the brain associated with movement disorders.

Abbott Laboratories (ABT 3.05%) announced on Friday that it's Infinity Deep Brain Stimulation (DPS) system had received approval from the Food and Drug Administration (FDA) to target specific areas of the brain associated with motor functions. More specifically, the expanded indication permits Abbott's DPS system to target the internal globus pallidus (GPi), a specific part of the brain that regulates voluntary movement. 

This specific part of the brain, when stimulated, has been associated with helping improve motor-function related Parkinson's symptoms. DPS therapy can also help Parkinson's patients who are dealing with side-effects from medications, such as involuntary muscle movements and spasms (also known as dyskinesia).

An MRI scan of a patients brain up close.

Image source: Getty Images.

The company noted that Infinity is the only directional DPS system that's been approved by the FDA to be used for all parts of the brain associated with movement associated disorders. In addition to being available in almost 30 countries around the world, the system can also be controlled with a nearby IOS device with Bluetooth technology, such as an iPhone.

A growing market

DPS systems are becoming an increasingly common type of treatment for a variety of brain-related disorders. Besides Parkinson's, depression is also another condition that's being treated with DPS technology with increasing success. Other conditions, such as schizophrenia and Alzheimer's, are also being tested at the moment as well.

In addition to this piece of news, Abbott recently reported strong fourth-quarter financial results. Most notably, the healthcare company's overall sales have increased by 7% in comparison to the same time last year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$109.45 (3.05%) $3.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.